Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma

Phase 2 Not yet recruiting 23 enrolled The First Affiliated Hospital with Nanjing Medical University

NaSingle-groupOpen-labelTreatment

Summary

To explore PFS, ORR (CR/CRu+PR), OS and side effects of piamprizumab combined with RMA in newly diagnosed PCNSL, so as to clarify the value of piamprizumab combined with RMA in the first-line treatment of PCNSL patients, and to clarify the clinical and biological factors affecting the efficacy

Timeline

Start: 2022-06-01
Primary completion: 2025-06-01
Completion: 2029-06-01

Publications

Shen HR, Wu JZ, Yin H, Du KX, Sibusiso L, Wu YF, Hua W, Li Y, Kong YL, Zhang XY, Gao R, Li JY, Wang L, Liang JH, Xu W. Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial. Blood Cancer J. 2026 Feb 11;16(1):23. doi: 10.1038/s41408-026-01450-w.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Penpulimab	Monoclonal antibody	200 mg	Intravenous
Background	Cytarabine	Small molecule	1000 mg/m2	Intravenous
Background	Cytarabine	Small molecule	2000 mg/m2	Intravenous
Background	Methotrexate	Small molecule	3500 mg/m2	Intravenous
Background	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous

Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma

Summary

Timeline

Publications

Drugs

Indications